

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A method of inhibiting osteoclast-mediated bone resorption, comprising inhibiting activity of a gene product encoded by osteoclast associated gene OC14, wherein said osteoclast-associated gene OC14 comprises the nucleotide sequence of SEQ ID NO: 50, wherein said activity of a gene product encoded by OC14 is inhibited by administering a compound that inhibits the ~~activity~~ expression of said gene product, and wherein the activity of said gene product is decreased by at least 10% in the presence of said compound, as compared to the activity of said gene product in the absence of said compound.
2. - 25. (Cancelled)
26. (Previously Presented) The method of claim 1, wherein said compound is selected from the group consisting of a fusion protein, a polypeptide, a peptidomimetic, an antisense polynucleotide, a prodrug, an antibody, a small molecule inhibitor, or a ribozyme.
27. (Previously Presented) The method of claim 1, wherein the activity of said gene product is decreased by at least 1.5-fold in the presence of said compound, as compared to the activity of said gene product in the absence of said compound.
28. (Previously Presented) The method of claim 1, wherein the activity of said gene product is decreased by at least 3-fold in the presence of said compound, as compared to the activity of said gene product in the absence of said compound.
29. (Previously Presented) The method of claim 1, wherein the activity of said gene product is decreased by at least 5-fold in the presence of said compound, as compared to the activity of said gene product in the absence of said compound.
30. (Cancelled)

31. (Previously Presented) The method of claim 1, wherein the activity of said gene product is decreased by at least 50% in the presence of said compound, as compared to the activity of said gene product in the absence of said compound.

32. (Previously Presented) The method of claim 1, wherein the activity of said gene product is decreased by at least 75% in the presence of said compound, as compared to the activity of said gene product in the absence of said compound.

33. (Previously Presented) The method of claim 1, wherein the activity of said gene product is decreased by at least 90% in the presence of said compound, as compared to the activity of said gene product in the absence of said compound.